Libranza, Susa O.

HRN: 23-84-19  Sex: Female

Patient Encounter


AMS Audit List

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
10/04/2023
METRONIDAZOLE 5MG/ML, 100ML (VIAL)
10/04/2023
10/11/2023
IV
500mg
TID
Amoebiasis
Waiting Final Action 
10/04/2023
CEFUROXIME 1.5GM (VIAL)
10/04/2023
10/11/2023
IV
1.5g
Q8hrs
UTI
Waiting Final Action 
10/08/2023
METRONIDAZOLE 500MG (TAB)
10/08/2023
10/11/2023
PO
500mg
TID
Amoebiasis
Waiting Final Action 

AMS Audit Form


Start Date: End Date:

Indication:

              

Type of Infection:

                             

           

Compliance to guidelines:



Initial appropriateness:



 If inappropriate:

           

Final appropriateness:



 If inappropriate:

              

Overall appropriateness: